<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02290886</url>
  </required_header>
  <id_info>
    <org_study_id>CeTMAd/ELA/2011</org_study_id>
    <nct_id>NCT02290886</nct_id>
  </id_info>
  <brief_title>A Multicenter Phase I/II Clinical Trial to Evaluate Safety of Mesenchymal Stem Cell in Patients With Amyotrophic Sclerosis Lateral</brief_title>
  <official_title>A Multicenter Phase I/II Clinical Trial, Randomized, Controlled With Placebo, Triple Blind to Evaluate Safety, and Indications of Efficiency of the Intravenous Administration of the Therapy With 3 Doses of MSC in Patients With ASL Moderated to Severe</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Iniciativa Andaluza en Terapias Avanzadas</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A multicenter phase I/II Clinical trial,randomized, controlled with placebo, triple blind to
      evaluate the safety of the intravenous administration of 3 doses of autologous mesenchymal
      stem cells cells from adipose tissue in patients with Amyotrophic Lateral Sclerosis (ALS).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A multicenter phase I/II Clinical trial,randomized, controlled with placebo, triple blind to
      evaluate the safety of the intravenous administration of 3 doses of autologous mesenchymal
      stem cells cells from adipose tissue in patients with Amyotrophic Lateral Sclerosis (ALS).

      40 patients will be enrolled and will be randomized into one of the following 4 arms:

        -  10 patients in the control group (placebo)

        -  10 patients received a dose of 1 million MSC / kg

        -  10 patients received a dose of 2 million MSC / kg.

        -  10 patients received a dose of 4 million MSC / kg

      The follow-up phase of each patient from the cell infusion/placebo will be 6 months.

      At the time that each patient completed the follow-up period (i.e., 6 months after the
      infusion of the cellular product or placebo), the blind will be open, and patients who have
      been assigned to the control group, will receive the cell product as secondary treatment.
      These patients will be randomized to receive each of the doses used in the first phase. From
      this point, they begin a second period of follow up of 6 months.

      In addition, after 6 months of MSC infusion, every patient will continue in an open extension
      study for 36 months to assess the safety of MSC.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2014</start_date>
  <completion_date type="Anticipated">July 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of adverse serious unexpected reactions or not, attributable to the treatment (SUSSARs or SAE)</measure>
    <time_frame>6 months</time_frame>
    <description>To evaluate the safety of the intravenous administration of 3 doses of autologous mesenchymal stem cells (MSC) from adipose tissue in patients with Amyotrophic lateral Sclerosis (ALS) ABSENCE of: complications in the place of the infusion, appearance of a new neurological effect not attributable to the natural progression of this pathology and adverse serious unexpected reactions or not, attributable to the treatment (SUSSARs or SAE)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Complications in the place of the infusion</measure>
    <time_frame>6 months</time_frame>
    <description>To evaluate the safety of the intravenous administration of 3 doses of autologous</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Appearance of a new neurological effect not attributable to the natural progression of this pathology</measure>
    <time_frame>6 months</time_frame>
    <description>To evaluate the safety of the intravenous administration of 3 doses of autologous</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in the progression of the disease (modifications in the scale of functionality of the ALS)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the degree of muscular force</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the vital forced capacity</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of the muscular mass estimated by Nuclear Magnetic Resonance (NMR) of the upper and low extremities</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in neurophysiological parameters and of quality of life</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need and time to tracheotomy or permanent assisted ventilation</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intravenous administration of placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1 million of MSC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous administration of 1 million of MSC/ kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2 million of MSC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous administration of 2 million of MSC/ kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4 million of MSC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous administration of 4 million of MSC/ kg</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Intravenous administration of placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravenous administration of 1 million of MSC</intervention_name>
    <arm_group_label>1 million of MSC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravenous administration of 2 million of MSC</intervention_name>
    <arm_group_label>2 million of MSC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravenous administration of 4 million of MSC</intervention_name>
    <arm_group_label>4 million of MSC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Women and males over 18-year-old.

          2. Good understanding of the protocol and aptitude to grant the informed assent.

          3. Diagnosis of sporadic ALS, with diagnosis of certainty, that is to say, definite or
             probable, in agreement with the criteria of &quot;El Escorial&quot;, of the World Federation of
             Neurology.

          4. Forced vital capacity of at least 50 % of the one that would correspond to them for
             sex, height and age.

          5. More than 6 and less than 36 months of evolution of the disease (from the beginning of
             the symptoms).

          6. Possibility of obtaining, at least, 50gr of adipose tissue.

          7. Treatment with riluzole, for at least, a month before the inclusion.

        Exclusion Criteria:

          1. Any concomitant disease that under investigator's criteria could concern the measures
             of the clinical variables of the trial (hepatic, renal or cardiac insufficiency,
             diabetes mellitus, etc).

          2. Previous therapy with stem cells.

          3. Participation in another clinical trial during 3 months previous to the entry in this
             trial.

          4. Any disease lymphoproliferative

          5. Tracheostomy and /or gastrostomy.

          6. Haemophilia, diathesis hemorrhagic or anticoagulative current therapy.

          7. Hypersensitivity known to the bovine foetal whey or the gentamicin.

          8. Medical precedents of infection of the HIV or any serious condition of
             immunocompromised.

          9. Positive HBV or HCV serology

         10. Levels of creatinine in whey &gt; 3.0 in subjects not submitted to haemodialysis.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Óscar Fernández, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Regional U. de Málaga</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Óscar Fernández, MD</last_name>
    <email>oscar.fernandez.sspa@juntadeandalucia.es</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ana Cardesa</last_name>
    <phone>+ 34 955 04 83 66</phone>
    <email>ana.cardesa@juntadeandalucia.es</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Regional Universitario Reina Sofía</name>
      <address>
        <city>Cordoba</city>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eduardo Aguera, MD</last_name>
      <email>eduaguera@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Regional Universitario de Málaga</name>
      <address>
        <city>Málaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Victoria Fernández, MD</last_name>
      <phone>951291135</phone>
      <email>victoriae.fernandez.sspa@juntadeandalucia.es</email>
    </contact>
    <investigator>
      <last_name>Victoria Fernández, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen Macarena, Servicio de Neurología</name>
      <address>
        <city>Seville</city>
        <zip>41009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guillermo Navarro, MD</last_name>
      <email>guillermo.navarro.sspa@juntadeandalucia.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocío</name>
      <address>
        <city>Seville</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Celedonio Marquez, MD</last_name>
      <email>celedonio.marquez.sspa@juntadeandalucia.es</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 9, 2014</study_first_submitted>
  <study_first_submitted_qc>November 11, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 14, 2014</study_first_posted>
  <last_update_submitted>April 16, 2018</last_update_submitted>
  <last_update_submitted_qc>April 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>safety evaluation</keyword>
  <keyword>intravenous administration</keyword>
  <keyword>3 doses of autologous MSC</keyword>
  <keyword>ALS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

